# DELTA DETECTION AUDIT REPORT (AUDIT 2)
**Subject:** Corrected WP-P0-12 Production Admission Packet (`subject/P012_PRODUCTION_ADMISSION_PACKET.md`, 291 lines)  
**Packet Directory:** [`C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B)  
**Auditor:** `gemini-3.8-flash-high` (Supplemental Read-Only Detection Auditor / `SUPPLEMENTAL_UNEXECUTED`)  
**Verdict:** **PASS**

---

## Executive Summary

The corrected owner-facing decision packet (`P012_PRODUCTION_ADMISSION_PACKET.md`, expanded from 121 to 291 lines) was audited against all canonical staged sources, the previous audit report (`prior/GEMINI_AUDIT_1_REPORT.md`), and the correction lane claims (`subject/DISPOSITION_FIX1.md`).

All **9 prior findings (F-01 through F-09)** have been verified as **RESOLVED**:
1. **F-01 (BLOCKING):** Fee Choice B3 (`first authenticated native fill`) and Funding Effective Interval F-13 are strictly separated everywhere in the packet (Pipeline item 5, Table B line 126, Table C lines 176–178, and Owner Decisions 4 & 5).
2. **F-02 (BLOCKING):** The invented citation `03_PRODUCTION_CLOSURE_MATRIX.md:404` has been removed. Rows 24–27 are cited strictly to line 53 of the matrix and treated as grouped shared requirements; the five residual obligations are cited exclusively to the amendment and lead note.
3. **F-03 (BLOCKING):** The assertion that the owner "is confirmed as the qualified human reviewer" has been completely eliminated. Reviewer identity is posed as an open WHO question (Decision 1) with explicit disclaimers that the role is not decided and that model outputs cannot substitute for human review.
4. **F-04 (CORRECTION):** Staged copies of `DEPLOY_LINUX_README.md` and `MASTER_WORK_PACKAGE_excerpt.md` are present within the packet directory; all citations were re-opened and verified against real lines.
5. **F-05 (CORRECTION):** The filename typo `PATH_D_DECISION_DECISION_SIGNED` has been corrected across all occurrences.
6. **F-06 (CORRECTION):** All 235 citation instances across 115 distinct `path:line` pairs were opened and checked without sampling. Every single pair is classified as **EQUAL** (115/115); zero wrong lines and zero missing citations remain.
7. **F-07 (CORRECTION):** Table A (10 rows) and Table B (27 risk IDs across 24 rows) quote "settled choice" and "remaining closure" verbatim from `sources/03_PRODUCTION_CLOSURE_MATRIX.md` with no truncation or paraphrasing.
8. **F-08 (NIT):** Mojibake encoding damage (`?1`) has been replaced with clean ASCII `>= 1`.
9. **F-09 (NIT):** Owner Decision 1 is syntactically matched as a WHO question with a who-shaped answer ("name the experienced engineer...").

No new blocking issues, hedge upgrades, invented citations, or ungrounded authority expansions were detected.

---

## (a) Delta Findings Table (F-01 .. F-09)

| Finding ID | Severity | Status | Proof Lines in Packet | Verification & Analysis Details |
|---|---|---|---|---|
| **F-01** | BLOCKING | **RESOLVED** | Lines 49–55, 126, 176–178, 227–234, 235–241 | **Separation of Fee B3 and Funding F-13:**<br>• Line 49 explicitly mandates: *"Fee B3 and funding F-13 are separate. Fee B3 is the first-authenticated-fill fee boundary; funding uses A1 forward-only settlement capture and A2 M pending after >= 1 observation. Do not substitute the fee boundary for the funding interval."*<br>• Table B (line 126) for F-13 states: *"YES - choose funding period semantics separately from fee B3; recommended answer is forward-only funding interval at or after the signed lower bound, with M pending."*<br>• Table C (lines 176–178) separates `Funding M`, `First-authenticated-fill fee boundary`, and `Forward funding interval` into individual gates.<br>• Section 6 separates Question 4 (*"What are the funding period semantics for F-13?"*) and Question 5 (*"What is the fee interval boundary for C-6 and related fee evidence?"*), with distinct consequences and citations to [`P012_ACCEPTANCE_AMENDMENT_20260913.md:211`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/P012_ACCEPTANCE_AMENDMENT_20260913.md#L211) (`PD-FUND-START`). |
| **F-02** | BLOCKING | **RESOLVED** | Lines 108–110, 137, 163, 174, 274–278 | **Matrix Line Limits and Attribution of Rows 24–27:**<br>• The nonexistent citation `:404` is removed. All 38 citations to [`03_PRODUCTION_CLOSURE_MATRIX.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/03_PRODUCTION_CLOSURE_MATRIX.md) fall between lines 7 and 62 (file has 66 lines).<br>• Rows 24–27 are cited strictly to matrix line 53 (`| 24–27 | run-manifest digests + effective intervals | **four retained shared requirements** (grouped; per-ID ordering unavailable)...`).<br>• Section 7 item 4 (lines 274–278) explicitly documents that rows 24–27 remain grouped as four shared requirements with per-ID ordering unavailable, citing matrix line 53 and amendment lines 395–397. |
| **F-03** | BLOCKING | **RESOLVED** | Lines 4, 10–13, 80, 103, 114, 117, 125, 136, 164, 168, 174, 178, 179, 195–200, 204–206, 262 | **Elimination of Reviewer Identity Upgrades:**<br>• Line 4 states the packet *"does not... replace a qualified human review."*<br>• Line 80 & 103 preserve OPEN-01's exact text: Section-16 human review *by the owner at build acceptance* (`OPEN_ITEMS_SOURCE.json:22`), distinct from generic specialist review.<br>• Lines 117 (I-4), 125 (C-12), and 136 (F-23) pose reviewer selection as an open question, explicitly warning in C-12: *"do not claim the owner is already confirmed."*<br>• Table C line 179 for `Experienced-human money gate` poses *"YES - who is that reviewer?"*<br>• Owner Decision 1 (lines 204–206) asks *"Who is the qualified human reviewer for I-4, C-12, F-23, and the experienced-human money gate?"* and recommends: *"name the experienced engineer / qualified record reviewer. If Baris intends to be that person, say so explicitly; the policy is satisfied only if he meets the wording. This is not already decided."* |
| **F-04** | CORRECTION | **RESOLVED** | Lines 30–35, 70–74, 245–248, 288–290 | **Inclusion of External Provenance Files:**<br>• Staged copies [`sources/DEPLOY_LINUX_README.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/DEPLOY_LINUX_README.md) and [`sources/MASTER_WORK_PACKAGE_excerpt.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/MASTER_WORK_PACKAGE_excerpt.md) are present and readable inside the packet.<br>• All cited lines (`README.md:137, 141, 145-148` and `MASTER_WORK_PACKAGE...:400, 405, 406, 407, 1069`) were read directly and match the quoted excerpts bit-for-bit. |
| **F-05** | CORRECTION | **RESOLVED** | Lines 45, 50, 51, 57, 175, 176, 177, 178, 185, 187, 219, 231, 238, 264 | **Correction of Path D Filename Typo:**<br>• The duplicated token `DECISION_DECISION` is completely absent.<br>• All 14 citations to the signed decision cite the canonical name [`PATH_D_DECISION_SIGNED_20260912.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/PATH_D_DECISION_SIGNED_20260912.md). |
| **F-06** | CORRECTION | **RESOLVED** | Lines 5, 50, 51, 53, 54, 68, 93–99, 141, 142, 145–151, 224–226, 283 | **Comprehensive Resolution of Citation Offsets:**<br>• All 17 wrong-line citations reported in Audit 1 have been corrected (e.g. `LEAD_NOTE.md:10`, `PATH_D_DECISION_PACKET.md:71` for M, `P012_ACCEPTANCE_AMENDMENT_20260913.md:367` for cadence, `03_PRODUCTION_CLOSURE_MATRIX.md:31` for I-2, `:32` for I-3, etc.).<br>• Full verification of all 115 distinct pairs confirmed 100% `EQUAL` match across the entire packet (see Section (c)). |
| **F-07** | CORRECTION | **RESOLVED** | Lines 80–89, 114–137 | **Verbatim Restoration of Matrix Table Cells:**<br>• Table A OPEN-04 now carries `` `BPS_OF_REFERENCE_V1`, `slippage_bps = 0` explicit zero (add. 15 row 38) ``.<br>• Table A OPEN-06 restores the full list: `RETAIN ALL P01-P03/P05-P18/P24-P26; P04 RETIRE, P19 RETIRE, P20 RETAIN, P21 RETIRE-implicitness, P22 STOP_FIRST, P23 N/A (add. 16 row 45)`.<br>• Table A OPEN-07 and OPEN-08 restore the addendum references.<br>• Table B I-2, I-3, I-4, I-5, and 24–27 match every character of the source matrix without paraphrase or truncation (see Section (b)). |
| **F-08** | NIT | **RESOLVED** | Lines 49, 176, 228 | **Elimination of Encoding Corruption:**<br>• Corrupted `?1` replaced with clean ASCII `>= 1`. Checked in UTF-8; no invalid byte sequences or mojibake remain. |
| **F-09** | NIT | **RESOLVED** | Lines 204–206 | **Grammatical Syntax Alignment:**<br>• Question 1 is a WHO question (*"Who is the qualified human reviewer..."*).<br>• The answer begins with a directive noun phrase (*"name the experienced engineer / qualified record reviewer..."*) rather than an incongruous "Yes". |

---

## (b) Row Completeness Tables

### 1. Table A Completeness (10 Section-19 OPEN Rows)

| Row | Plain Meaning in Packet | Settled Choice in Packet | Matrix Line 9–20 Text Match | Remaining Closure in Packet | Matrix Remaining Closure Match | Who Acts | Owner Decision Needed Now? |
|---|---|---|---|---|---|---|---|
| **OPEN-01** | First production InstrumentRecord source, product, symbol, and review path. | "Hyperliquid perp BTC from frozen doc set; record APPROVED (add. 16 row 42)" | **EQUAL** (verbatim :11) | "minimum_quantity: venue publishes none (recorded); **section-16 human review by owner at build acceptance**" | **EQUAL** (verbatim :11) | owner + venue | NO - evidence closes it (production record bytes + Section-16 review) |
| **OPEN-02** | Same-bar policy for acceptance-bearing runs. | "STOP_FIRST mandatory same-bar policy (add. 15 row 32)" | **EQUAL** (verbatim :12) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :12) | final production evidence/review | NO - reuse bounded fixtures, then final review |
| **OPEN-03** | Fee schedule, rounding, minimum fee, and liquidation-class applicability. | "fee table v1.1 + ADOPTED CLASS MAPPING (add. 16 row 43)" | **EQUAL** (verbatim :13) | "margin-call/liquidation class CANNOT MAP; rounding/minimum-fee not stated by frozen bytes" | **EQUAL** (verbatim :13) | venue | NO - venue evidence must close unstated fee facts |
| **OPEN-04** | Slippage model and zero slippage parameter. | "`BPS_OF_REFERENCE_V1`, `slippage_bps = 0` explicit zero (add. 15 row 38)" | **EQUAL** (verbatim :14) | "none listed" | **EQUAL** (verbatim :14) | local | NO - settled zero remains owner-declared rule |
| **OPEN-05** | Funding rules and same-timestamp snapshot ordering. | "funding rules APPROVED + same-timestamp snapshot INCLUDE (add. 16 row 42, 17 row 46)" | **EQUAL** (verbatim :15) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :15) | final production evidence/review | NO - final production applicability/review required |
| **OPEN-06** | Which execution-profile controls are retained, retired, or stopped first. | "RETAIN ALL P01-P03/P05-P18/P24-P26; P04 RETIRE, P19 RETIRE, P20 RETAIN, P21 RETIRE-implicitness, P22 STOP_FIRST, P23 N/A (add. 16 row 45)" | **EQUAL** (verbatim :16) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :16) | final production evidence/review | NO - final production applicability/review required |
| **OPEN-07** | Funding/events mapping obligations that integration must later carry. | "mapping APPROVED as closure evidence; unmapped fields + deployed-v4 non-materialization = RECORDED INTEGRATION OBLIGATIONS (add. 15 row 41, 16 row 42)" | **EQUAL** (verbatim :17) | "unmapped funding fields without direct Bridge source" | **EQUAL** (verbatim :17) | integration | NO - direct Bridge source mapping remains needed |
| **OPEN-08** | Additional numeric/event bounds. | "no additional bounds (add. 15 row 33)" | **EQUAL** (verbatim :18) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :18) | final production evidence/review | NO - final production applicability/review required |
| **OPEN-09** | Additive result/event schema and protected build authorization path. | "additive result/event schema (add. 15 row 34); build authorization = add. 16 T0 path" | **EQUAL** (verbatim :19) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :19) | final production evidence/review | NO - production receipt must carry protected-scope approval |
| **OPEN-10** | PnL basis guards around gross-minus-fees outputs. | "guards keep GROSS-MINUS-FEES (add. 15 row 35)" | **EQUAL** (verbatim :20) | "Reuse existing bounded fixture evidence; final production applicability/review still required" | **EQUAL** (verbatim :20) | final production evidence/review | NO - final production applicability/review required |

*Table A completeness verdict:* **10/10 rows present; all cells EQUAL (verbatim).**

---

### 2. Table B Completeness (27 Signed Residual Risks)

| ID | Plain Meaning in Packet | Settled Choice in Packet | Matrix Line 30–53 Text Match | Remaining Closure in Packet | Matrix Remaining Closure Match | Who Acts | Owner Decision Needed Now? |
|---|---|---|---|---|---|---|---|
| **I-1** | Instrument status remains refused. | "addendum-16 selection applied; admission still refused" | **EQUAL** (:30) | "real qualified human review + full admission evidence" | **EQUAL** (:30) | review | NO - close only with real qualified review + evidence |
| **I-2** | Price tick scalar remains null under the retained typed policy. | "scalar `null`; typed policy `HYPERLIQUID_PX_V1` implemented" | **EQUAL** (:31) | "Scalar remains null; reuse accepted PR176 typed-policy/precision evidence; formal signed residual not retired. This prep did not rerun that acceptance. No new scalar demand." | **EQUAL** (:31) | local reuse | NO - reuse PR176 evidence; no new scalar demand |
| **I-3** | Minimum quantity is still a distinct venue fact. | "`null`; `minimum_notional: 10`, `quantity_step: 0.00001`; no quantity floor" | **EQUAL** (:32) | "Minimum_quantity remains a distinct unclosed source fact; venue quantity minimum if stated; never infer zero" | **EQUAL** (:32) | venue | YES - accept owner-guard route only as guard, not venue fact |
| **I-4** | Instrument human reviewer is not filled. | "`human_reviewer: null` (key present)" | **EQUAL** (:33) | "real **qualified** human review of completed record" | **EQUAL** (:33) | review | YES - WHO: name experienced engineer / qualified reviewer |
| **I-5** | Aggregate source fingerprint is already implemented and verified. | "implemented + verified (`source_sha256 = da2bf1fe…`, five sources)" | **EQUAL** (:34) | "none" | **EQUAL** (:34) | local done | NO - no closure item listed |
| **C-6** | Cost effective interval start is implemented but historical tier coverage remains unproved. | "start implemented (`2026-09-06T14:00:30Z`)" | **EQUAL** (:35) | "historical tier coverage — Sept-8 snapshot does not prove earlier tier history" | **EQUAL** (:35) | venue | NO - keep historical coverage open; do not backdate |
| **C-7** | Fee rounding rule is still refused. | "KEEP_REFUSED; absence proof attached" | **EQUAL** (:36) | "authoritative precision/direction/per-fill scope" | **EQUAL** (:36) | venue | NO - needs authoritative precision/direction/per-fill scope |
| **C-8** | Fixed component is still refused. | "KEEP_REFUSED; absence proof" | **EQUAL** (:37) | "authoritative applicability/absence + exceptions" | **EQUAL** (:37) | venue | NO - needs authoritative applicability/absence + exceptions |
| **C-9** | Minimum fee is still refused. | "KEEP_REFUSED; absence proof" | **EQUAL** (:38) | "authoritative minimum/application granularity" | **EQUAL** (:38) | venue | NO - needs authoritative minimum/application granularity |
| **C-10** | Account tier evidence exists but is not incorporated. | "collected, not incorporated" | **EQUAL** (:39) | "historical coverage + actual fee applicability" | **EQUAL** (:39) | venue/owner | YES - decide real account tier only after evidence; answer: WAIT |
| **C-11** | Liquidation class is not mapped. | "CANNOT_MAP refusal (`MARGIN_CALL_LIQUIDATION`)" | **EQUAL** (:40) | "complete applicable economic mapping + historical scope" | **EQUAL** (:40) | venue | NO - needs complete economic mapping + historical scope |
| **C-12** | Cost human reviewer is absent. | "key absent (not null)" | **EQUAL** (:41) | "real **qualified** human review" | **EQUAL** (:41) | review | YES - WHO: name qualified reviewer; do not claim confirmed |
| **F-13** | Funding effective interval is unresolved. | "`null`" | **EQUAL** (:42) | "complete period + interval semantics" | **EQUAL** (:42) | venue/owner | YES - choose funding semantics separately from fee B3 |
| **F-14** | Production funding events are missing. | "`null`; `REFUSED_MISSING_PRODUCTION_FUNDING_EVENTS`" | **EQUAL** (:43) | "complete admissible event series" | **EQUAL** (:43) | venue | NO - needs complete admissible event series |
| **F-15** | Raw stamps exist but are not admitted. | "4 raw stamps (+31–53 ms) collected, not admitted" | **EQUAL** (:44) | "payment/interval association" | **EQUAL** (:44) | venue | NO - needs payment/interval association |
| **F-16** | Funding event ID/dedup is absent. | "none admitted" | **EQUAL** (:45) | "source-bound unique identity + dedup/exact-once" | **EQUAL** (:45) | venue | NO - needs unique identity + exact-once proof |
| **F-17** | Raw rate rows exist but are not admitted. | "4 rows `0.0000125`, not admitted" | **EQUAL** (:46) | "bind authoritative rates to admitted payments" | **EQUAL** (:46) | venue | NO - needs authoritative rate binding to admitted payments |
| **F-18** | Positive-rate payer rule lacks per-event objects. | "`LONG` rule implemented; no per-event objects" | **EQUAL** (:47) | "proven convention onto sourced events" | **EQUAL** (:47) | venue | NO - needs proven convention on sourced events |
| **F-19** | Oracle price samples do not prove settlement valuation. | "3 samples; no settlement valuation" | **EQUAL** (:48) | "authoritative source + defensible per-payment association" | **EQUAL** (:48) | venue | NO - needs authoritative source + defensible association |
| **F-20** | Oracle price source is missing per event. | "`SPOT_ORACLE` rule; per-event provenance missing" | **EQUAL** (:49) | "true valuation-source identity per event" | **EQUAL** (:49) | venue | NO - needs true valuation-source identity per event |
| **F-21** | Event provenance is raw capture metadata only. | "raw capture metadata only" | **EQUAL** (:50) | "bind request/source/bytes/time/event + coverage" | **EQUAL** (:50) | venue | NO - needs request/source/bytes/time/event coverage |
| **F-22** | Source-event digest is absent. | "none admitted" | **EQUAL** (:51) | "deterministic raw→event digest, source-bound" | **EQUAL** (:51) | venue | NO - needs deterministic raw->event digest, source-bound |
| **F-23** | Funding human reviewer is absent. | "key absent (not null)" | **EQUAL** (:52) | "real **qualified** human review after complete evidence" | **EQUAL** (:52) | review | YES - WHO: name qualified reviewer after complete evidence |
| **24–27** | Four shared run-manifest requirements are grouped; no per-ID ordering is available. | "**four retained shared requirements** (grouped; per-ID ordering unavailable); no canonical production pointers" | **EQUAL** (:53) | "derive from completed accepted records" | **EQUAL** (:53) | local derived | NO - derive from completed records; do not invent identities |

*Table B completeness verdict:* **All 27 risk IDs present across 24 table rows (with 24–27 grouped per matrix instruction); all cells EQUAL (verbatim).**

---

## (c) Full Citation Verification Table (All 115 Distinct Pairs)

Every one of the 115 distinct `path:line` pairs cited in the packet (235 total citations) was individually verified against the staged files:

### 1. `03_PRODUCTION_CLOSURE_MATRIX.md` (38 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 1 | `03_PRODUCTION_CLOSURE_MATRIX.md:7` | 102 | `All ten are disposition APPLICABLE and formally OPEN for production...` | **EQUAL** |
| 2 | `03_PRODUCTION_CLOSURE_MATRIX.md:11` | 80, 92 | `\| OPEN-01 \| Hyperliquid perp BTC... \| minimum_quantity... \| owner + venue \|` | **EQUAL** |
| 3 | `03_PRODUCTION_CLOSURE_MATRIX.md:12` | 81, 93 | `\| OPEN-02 \| STOP_FIRST mandatory same-bar policy... \| Reuse existing...` | **EQUAL** |
| 4 | `03_PRODUCTION_CLOSURE_MATRIX.md:13` | 82, 94 | `\| OPEN-03 \| fee table v1.1 + ADOPTED CLASS MAPPING... \| margin-call...` | **EQUAL** |
| 5 | `03_PRODUCTION_CLOSURE_MATRIX.md:14` | 83, 95 | `\| OPEN-04 \| BPS_OF_REFERENCE_V1, slippage_bps = 0 explicit zero...` | **EQUAL** |
| 6 | `03_PRODUCTION_CLOSURE_MATRIX.md:15` | 84, 96 | `\| OPEN-05 \| funding rules APPROVED + same-timestamp snapshot INCLUDE...` | **EQUAL** |
| 7 | `03_PRODUCTION_CLOSURE_MATRIX.md:16` | 85, 97 | `\| OPEN-06 \| RETAIN ALL P01-P03/P05-P18/P24-P26...` | **EQUAL** |
| 8 | `03_PRODUCTION_CLOSURE_MATRIX.md:17` | 86, 98 | `\| OPEN-07 \| mapping APPROVED as closure evidence...` | **EQUAL** |
| 9 | `03_PRODUCTION_CLOSURE_MATRIX.md:18` | 87, 99 | `\| OPEN-08 \| no additional bounds (add. 15 row 33)...` | **EQUAL** |
| 10 | `03_PRODUCTION_CLOSURE_MATRIX.md:19` | 88, 100 | `\| OPEN-09 \| additive result/event schema...` | **EQUAL** |
| 11 | `03_PRODUCTION_CLOSURE_MATRIX.md:20` | 89, 101 | `\| OPEN-10 \| guards keep GROSS-MINUS-FEES...` | **EQUAL** |
| 12 | `03_PRODUCTION_CLOSURE_MATRIX.md:26` | 109, 272 | `Numbering preserved. Source: PRIOR_CHECKLIST.md:23-48; residual inventory...` | **EQUAL** |
| 13 | `03_PRODUCTION_CLOSURE_MATRIX.md:30` | 114, 140 | `\| I-1 \| instrument /status \| addendum-16 selection applied...` | **EQUAL** |
| 14 | `03_PRODUCTION_CLOSURE_MATRIX.md:31` | 115, 141 | `\| I-2 \| /price_tick \| scalar null; typed policy HYPERLIQUID_PX_V1...` | **EQUAL** |
| 15 | `03_PRODUCTION_CLOSURE_MATRIX.md:32` | 116, 142 | `\| I-3 \| /minimum_quantity \| null; minimum_notional: 10...` | **EQUAL** |
| 16 | `03_PRODUCTION_CLOSURE_MATRIX.md:33` | 117, 143, 207 | `\| I-4 \| instrument human reviewer \| human_reviewer: null (key present)...` | **EQUAL** |
| 17 | `03_PRODUCTION_CLOSURE_MATRIX.md:34` | 118, 144 | `\| I-5 \| aggregate source fingerprint \| implemented + verified...` | **EQUAL** |
| 18 | `03_PRODUCTION_CLOSURE_MATRIX.md:35` | 119, 145 | `\| C-6 \| cost effective interval \| start implemented (2026-09-06T14:00:30Z)...` | **EQUAL** |
| 19 | `03_PRODUCTION_CLOSURE_MATRIX.md:36` | 120, 146 | `\| C-7 \| fee rounding rule \| KEEP_REFUSED; absence proof attached...` | **EQUAL** |
| 20 | `03_PRODUCTION_CLOSURE_MATRIX.md:37` | 121, 147 | `\| C-8 \| fixed component \| KEEP_REFUSED; absence proof...` | **EQUAL** |
| 21 | `03_PRODUCTION_CLOSURE_MATRIX.md:38` | 122, 148 | `\| C-9 \| minimum fee \| KEEP_REFUSED; absence proof...` | **EQUAL** |
| 22 | `03_PRODUCTION_CLOSURE_MATRIX.md:39` | 123, 149, 223 | `\| C-10 \| account tier evidence \| collected, not incorporated...` | **EQUAL** |
| 23 | `03_PRODUCTION_CLOSURE_MATRIX.md:40` | 124, 150 | `\| C-11 \| liquidation class \| CANNOT_MAP refusal (MARGIN_CALL_LIQUIDATION)...` | **EQUAL** |
| 24 | `03_PRODUCTION_CLOSURE_MATRIX.md:41` | 125, 151, 208 | `\| C-12 \| cost human reviewer \| key absent (not null)...` | **EQUAL** |
| 25 | `03_PRODUCTION_CLOSURE_MATRIX.md:42` | 126, 152, 230 | `\| F-13 \| funding effective interval \| null...` | **EQUAL** |
| 26 | `03_PRODUCTION_CLOSURE_MATRIX.md:43` | 127, 153 | `\| F-14 \| funding events \| null; REFUSED_MISSING_PRODUCTION_FUNDING_EVENTS...` | **EQUAL** |
| 27 | `03_PRODUCTION_CLOSURE_MATRIX.md:44` | 128, 154 | `\| F-15 \| event timestamp \| 4 raw stamps (+31–53 ms) collected...` | **EQUAL** |
| 28 | `03_PRODUCTION_CLOSURE_MATRIX.md:45` | 129, 155 | `\| F-16 \| funding event ID \| none admitted...` | **EQUAL** |
| 29 | `03_PRODUCTION_CLOSURE_MATRIX.md:46` | 130, 156 | `\| F-17 \| raw rate \| 4 rows 0.0000125, not admitted...` | **EQUAL** |
| 30 | `03_PRODUCTION_CLOSURE_MATRIX.md:47` | 131, 157 | `\| F-18 \| positive-rate payer \| LONG rule implemented...` | **EQUAL** |
| 31 | `03_PRODUCTION_CLOSURE_MATRIX.md:48` | 132, 158 | `\| F-19 \| oracle price \| 3 samples; no settlement valuation...` | **EQUAL** |
| 32 | `03_PRODUCTION_CLOSURE_MATRIX.md:49` | 133, 159 | `\| F-20 \| oracle price source \| SPOT_ORACLE rule; per-event provenance...` | **EQUAL** |
| 33 | `03_PRODUCTION_CLOSURE_MATRIX.md:50` | 134, 160 | `\| F-21 \| event provenance \| raw capture metadata only...` | **EQUAL** |
| 34 | `03_PRODUCTION_CLOSURE_MATRIX.md:51` | 135, 161 | `\| F-22 \| source event digest \| none admitted...` | **EQUAL** |
| 35 | `03_PRODUCTION_CLOSURE_MATRIX.md:52` | 136, 162, 209 | `\| F-23 \| funding human reviewer \| key absent (not null)...` | **EQUAL** |
| 36 | `03_PRODUCTION_CLOSURE_MATRIX.md:53` | 110, 137, 163, 275 | `\| 24–27 \| run-manifest digests + effective intervals \| four retained...` | **EQUAL** |
| 37 | `03_PRODUCTION_CLOSURE_MATRIX.md:59` | 103 | `- Human review contract preserved exactly. OPEN-01 expressly references...` | **EQUAL** |
| 38 | `03_PRODUCTION_CLOSURE_MATRIX.md:62` | 104 | `- Overlap (27 risks vs 10 OPEN rows) is mapped, not counted as closure...` | **EQUAL** |

---

### 2. `P012_ACCEPTANCE_AMENDMENT_20260913.md` (19 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 39 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:3` | 263 | `Status: RECORDED AMENDMENT / NONACCEPTING. The owner approved...` | **EQUAL** |
| 40 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:28` | 6 | `- Class B — explicitly open production-admission follow-up. Class B rows are not closed,` | **EQUAL** |
| 41 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:29` | 7 | `  waived, weakened or reinterpreted by this amendment. Each carries its evidence requirement, its` | **EQUAL** |
| 42 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:32` | 8 | `A row being Class B never means "resolved"; it means "outside the narrowed acceptance object and` | **EQUAL** |
| 43 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:33` | 9 | `still open". No Class B row may be declared closed by the label in §1.` | **EQUAL** |
| 44 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:144` | 164, 199, 212 | `\| SPECIALIST \| CT13/…/REVIEW_POLICY.md:73-76... \| Bounded specialist review...` | **EQUAL** |
| 45 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:202` | 165, 190, 240 | `\| PD-B3 \| …SIGNED_20260912.md:7; PATH_D_DECISION_PACKET.md:103 \| Choice B3 = B...` | **EQUAL** |
| 46 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:203` | 166, 191, 241 | `\| PD-B3-FILL \| P/RATIFICATION_DRAFTS_UNEXECUTED/REAL_OBSERVATION_INTAKE.md:17...` | **EQUAL** |
| 47 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:211` | 55, 167, 193, 234 | `\| PD-FUND-START \| CONTROL_RECONCILIATION.md:29... \| Funding interval lower bound...` | **EQUAL** |
| 48 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:212` | 168, 200 | `\| PD-MONEY-GATE \| CONTROL_RECONCILIATION.md:39... \| "the experienced-human money gate is separate"` | **EQUAL** |
| 49 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:337` | 224 | `4. ASSUMPTION — base tier-0 selection. tier_selection_basis is` | **EQUAL** |
| 50 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:338` | 225 | `   OWNER_APPROVED_BASE_TIER_0_WITH_ACCOUNT_EVIDENCE_RESIDUAL; account-tier evidence is collected` | **EQUAL** |
| 51 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:339` | 226 | `   but not incorporated (…BASE-TIER0-V2.json:93; C-10).` | **EQUAL** |
| 52 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:367` | 68, 283 | `    position value"; settlement cadence is not established` | **EQUAL** |
| 53 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:375` | 174, 182, 269, 273 | `17. ASSUMPTION — counts quoted, not recomputed. "27 signed risks", "five residual obligations",` | **EQUAL** |
| 54 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:395` | 276 | `3. Risks 24-27 are not individually identified anywhere I read. The matrix groups them as` | **EQUAL** |
| 55 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:396` | 277 | `   "four retained shared requirements (grouped; per-ID ordering unavailable)" (:53). §2 therefore` | **EQUAL** |
| 56 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:397` | 278 | `   carries four rows R-24..R-27 whose per-ID content is not established. Only 23 of the 27` | **EQUAL** |
| 57 | `P012_ACCEPTANCE_AMENDMENT_20260913.md:403` | 174, 183, 270 | `5. The five residual obligations are nowhere enumerated under that name. Sources give counts` | **EQUAL** |

---

### 3. `PATH_D_DECISION_PACKET.md` (18 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 58 | `PATH_D_DECISION_PACKET.md:25` | 44, 218 | `"Path 1" (self-observation on the owner's own account) is the complement...` | **EQUAL** |
| 59 | `PATH_D_DECISION_PACKET.md:47` | 60 | `Current status. Control-table row Funding F13–22 / OPEN05,07 — BLOCKED: production funding events...` | **EQUAL** |
| 60 | `PATH_D_DECISION_PACKET.md:61` | 61 | `- Refusals kept: no oracle value is admitted, derived or back-calculated [FF:80]...` | **EQUAL** |
| 61 | `PATH_D_DECISION_PACKET.md:63` | 62, 178, 194 | `- Evidence still required before admission: authenticated capture bytes with a digest domain...` | **EQUAL** |
| 62 | `PATH_D_DECISION_PACKET.md:64` | 63, 66, 281 | `- Residual risk: the Bridge accepts the venue's arithmetic without any independent revaluation...` | **EQUAL** |
| 63 | `PATH_D_DECISION_PACKET.md:70` | 52, 178, 192, 232 | `\| A1 \| Admission window \| Forward-only: only settlements captured live on the owner's own account...` | **EQUAL** |
| 64 | `PATH_D_DECISION_PACKET.md:71` | 53, 176, 188, 233 | `\| A2 \| Magnitude guard \| No cap \| Cap at M × the largest own-account observed rate...` | **EQUAL** |
| 65 | `PATH_D_DECISION_PACKET.md:90` | 255 | `- Source classes: HL_FEE_REPORTED_PER_FILL_V1 (admitted cost) + HL_FEE_SCHEDULE_ESTIMATOR_GUARDED_V1...` | **EQUAL** |
| 66 | `PATH_D_DECISION_PACKET.md:91` | 256 | `- Admitted inputs: the venue's own reported fee string on the owner's authenticated fill...` | **EQUAL** |
| 67 | `PATH_D_DECISION_PACKET.md:92` | 257 | `- Refusals kept: the literal EXACT_IDENTITY_V1 is never written...` | **EQUAL** |
| 68 | `PATH_D_DECISION_PACKET.md:93` | 258 | `- Guard margins: the estimator (taker 0.00045 / maker 0.00015 [FEE:61]) is computed alongside...` | **EQUAL** |
| 69 | `PATH_D_DECISION_PACKET.md:94` | 58, 175, 186 | `- Evidence still required before admission: N authenticated own-account native-BTC fills...` | **EQUAL** |
| 70 | `PATH_D_DECISION_PACKET.md:103` | 54, 177, 189, 239 | `\| B3 \| Effective interval start \| Keep 2026-09-06T14:00:30Z and accept unevidenced backdating...` | **EQUAL** |
| 71 | `PATH_D_DECISION_PACKET.md:164` | 179, 198 | `Exact review roster (T0). Fresh exact claude-opus-5 and gpt-5.6-sol, both xhigh...` | **EQUAL** |
| 72 | `PATH_D_DECISION_PACKET.md:191` | 46, 265 | `Standing exclusions, unchanged by this signature` | **EQUAL** |
| 73 | `PATH_D_DECISION_PACKET.md:192` | 47, 266 | ` - No deploy, live trading, TESTNET/mainnet contact, ARM, order placement, wallet or transfer` | **EQUAL** |
| 74 | `PATH_D_DECISION_PACKET.md:193` | 48, 267 | `   authority arises from this document. Path 1 needs its own separate explicit authorization.` | **EQUAL** |
| 75 | `PATH_D_DECISION_PACKET.md:250` | 67, 282 | `Where sources are silent (not filled in anywhere above): the funding settlement formula and cadence...` | **EQUAL** |

---

### 4. `06_HYPERLIQUID_SETUP.md` (10 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 76 | `06_HYPERLIQUID_SETUP.md:1` | 18 | `# 06 — Hyperliquid Setup Checklist (testnet = paper)` | **EQUAL** |
| 77 | `06_HYPERLIQUID_SETUP.md:14` | 19 | `\| \| Testnet (paper) \| Mainnet (real money) \|` | **EQUAL** |
| 78 | `06_HYPERLIQUID_SETUP.md:16` | 20, 216 | `\| Money \| Fake (faucet USDC) \| Real \|` | **EQUAL** |
| 79 | `06_HYPERLIQUID_SETUP.md:19` | 21, 217 | `\| Use for \| ALL of v1 (P0-P3) \| never in v1 \|` | **EQUAL** |
| 80 | `06_HYPERLIQUID_SETUP.md:21` | 22 | `Do everything below on **testnet**.` | **EQUAL** |
| 81 | `06_HYPERLIQUID_SETUP.md:37` | 24 | `Do NOT put your main wallet private key in the bridge. Hyperliquid supports **API wallets**` | **EQUAL** |
| 82 | `06_HYPERLIQUID_SETUP.md:38` | 25 | `(a.k.a. agent wallets): a delegated key that can place/cancel orders **but cannot withdraw funds**.` | **EQUAL** |
| 83 | `06_HYPERLIQUID_SETUP.md:45` | 26 | `4. The bridge signs orders with the API wallet key and references the main account address. Because` | **EQUAL** |
| 84 | `06_HYPERLIQUID_SETUP.md:46` | 27 | `   the API wallet cannot withdraw, even a fully compromised bridge cannot move your funds. **This is` | **EQUAL** |
| 85 | `06_HYPERLIQUID_SETUP.md:47` | 28 | `   the single most important safety property — never use the main wallet key.**` | **EQUAL** |

---

### 5. `COMMANDS.md` (8 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 86 | `COMMANDS.md:98` | 36 | `Gate: **KVM2-P4-03** — owner-only, separate from P4-01/P4-02, TESTNET only.` | **EQUAL** |
| 87 | `COMMANDS.md:100` | 37 | `Not scripted here on purpose. The values are typed by the owner into` | **EQUAL** |
| 88 | `COMMANDS.md:101` | 38 | `/etc/mtc-bridge/mtc-bridge.env (already 0600 root:root) through an editor on` | **EQUAL** |
| 89 | `COMMANDS.md:102` | 39 | `a trusted session. Names are listed in env/mtc-bridge.env.template.` | **EQUAL** |
| 90 | `COMMANDS.md:104` | 286 | `Post-conditions to assert afterwards, values never printed:` | **EQUAL** |
| 91 | `COMMANDS.md:263` | 40, 249 | `ARM (KVM2-P5-05/P5-05A), monitoring and backup provider provisioning` | **EQUAL** |
| 92 | `COMMANDS.md:265` | 41, 250 | `mainnet action. Each needs its own owner sentence, and none of them is implied` | **EQUAL** |
| 93 | `COMMANDS.md:266` | 42, 251 | `by completing every stage above.` | **EQUAL** |

---

### 6. `DEPLOY_LINUX_README.md` (6 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 94 | `DEPLOY_LINUX_README.md:137` | 30, 288 | `## Gate order (none of which this directory grants)` | **EQUAL** |
| 95 | `DEPLOY_LINUX_README.md:141` | 31, 245 | `3. KVM2-P4-03 — owner separately authorizes TESTNET-only secret provisioning.` | **EQUAL** |
| 96 | `DEPLOY_LINUX_README.md:145` | 32, 246 | `5. KVM2-P4-06 — owner authorizes exactly one first DISARMED start;` | **EQUAL** |
| 97 | `DEPLOY_LINUX_README.md:146` | 33 | `   KVM2-P4-07 executes it once (systemctl unmask then systemctl start).` | **EQUAL** |
| 98 | `DEPLOY_LINUX_README.md:147` | 34, 247 | `6. KVM2-P4-08 — rollback proof. KVM2-P4-08A/B — any recovery start.` | **EQUAL** |
| 99 | `DEPLOY_LINUX_README.md:148` | 35, 248 | `7. KVM2-P5-05/P5-05A — ARM, separately, once, never implied by any of the above.` | **EQUAL** |

---

### 7. `MASTER_WORK_PACKAGE_excerpt.md` (5 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 100 | `MASTER_WORK_PACKAGE_excerpt.md:400` | 70, 289 | `0400: ### WP-P0-12 · Kernel CORRECTED_VNEXT (M7b)` | **EQUAL** |
| 101 | `MASTER_WORK_PACKAGE_excerpt.md:405` | 71 | `0405: - **Protected surfaces:** **the strategy kernel.** · **Audit tier:** **T0**.` | **EQUAL** |
| 102 | `MASTER_WORK_PACKAGE_excerpt.md:406` | 72, 290 | `0406: - **Acceptance gate:** **no undocumented behavioural difference exists between P0-11 and P0-12.**...` | **EQUAL** |
| 103 | `MASTER_WORK_PACKAGE_excerpt.md:407` | 73 | `0407: - **Non-goals:** no new features; no optimization; no runtime wiring.` | **EQUAL** |
| 104 | `MASTER_WORK_PACKAGE_excerpt.md:1069` | 74 | `1069: \| **G3-K — Kernel, canonical simulator, and the T0 evidence gates that bless them** \| ...` | **EQUAL** |

---

### 8. `REVIEW_POLICY.md` (4 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 105 | `REVIEW_POLICY.md:73` | 10, 179, 195 | `Add a bounded specialist review for the first kernel, first live release, major security change,` | **EQUAL** |
| 106 | `REVIEW_POLICY.md:74` | 11, 179, 196, 210 | `or serious unresolved disagreement; name the question and stop condition. An experienced engineer` | **EQUAL** |
| 107 | `REVIEW_POLICY.md:75` | 12, 179, 197, 211 | `reviews before the first money-exposed release, not every package. These checks do not confer` | **EQUAL** |
| 108 | `REVIEW_POLICY.md:76` | 13 | `live-trading authority or replace exact protected acceptance contracts.` | **EQUAL** |

---

### 9. `TASK.md` (3 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 109 | `TASK.md:11` | 17 | `The owner said "TESTNET GO" today; KVM2 status at 08:40Z: service active, DISARMED...` | **EQUAL** |
| 110 | `TASK.md:13` | 285 | `- Do NOT read or quote any credential, wallet address, key or .env value. Everything here is documentary.` | **EQUAL** |
| 111 | `TASK.md:17` | 65, 280 | `2. The evidence pipeline in plain steps: what TESTNET GO starts; what a testnet capture can and cannot satisfy...` | **EQUAL** |

---

### 10. `PATH_D_DECISION_SIGNED_20260912.md` (3 pairs)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 112 | `PATH_D_DECISION_SIGNED_20260912.md:6` | 50, 176, 187, 231 | `A. Funding APPROVE A1=A A2=B (M PENDING, separate decision after N observations) A3=A` | **EQUAL** |
| 113 | `PATH_D_DECISION_SIGNED_20260912.md:7` | 51, 57, 175, 177, 185, 238 | `B. Fees APPROVE B1=C B2=C (5% rel; alt max(5%, 1e-6 USDC)) B3=B B4=A N=3 (maker, taker, near-$10)` | **EQUAL** |
| 114 | `PATH_D_DECISION_SIGNED_20260912.md:11` | 45, 219, 264 | `no deploy/live/TESTNET/mainnet/ARM/order/spend authority; T0 reviews, R29 redo, ratification, CI, protected merge remain.` | **EQUAL** |

---

### 11. `P012_RATIFICATION_LEAD_NOTE.md` (1 pair)

| # | Cited Path & Line | Packet Occurrence Line(s) | Source Staged Content | Classification |
|---|---|---|---|---|
| 115 | `P012_RATIFICATION_LEAD_NOTE.md:10` | 5, 174, 175, 176, 184 | `- Production admission is NOT granted. All 10 Section-19 OPEN rows, the 27 signed risks, the five residual obligations...` | **EQUAL** |

*Citation verification summary:*
• **Total Distinct Pairs Checked:** 115 / 115  
• **EQUAL:** 115 (100.0%)  
• **WRONG LINE:** 0 (0.0%)  
• **NOT FOUND:** 0 (0.0%)

---

## (d) New Audit Findings

**None.** (Zero BLOCKING, zero CORRECTION, zero NIT).  
The packet adheres to all documentary, sourcing, and authority boundaries.

---

## (e) Exact Native Read Coverage

All reads were conducted strictly through native `view_file` calls over files residing in `C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/` and repository root `AGENTS.md`. No view call exceeded 150 lines.

1. [`AGENTS.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/AGENTS.md) — Lines 1–64 (complete, 64 lines)
2. [`PACKET_SHA256SUMS.txt`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/PACKET_SHA256SUMS.txt) — Lines 1–19 (complete, 19 lines)
3. [`FILE_MAP.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/FILE_MAP.md) — Lines 1–17 (complete, 17 lines)
4. [`subject/DISPOSITION_FIX1.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/subject/DISPOSITION_FIX1.md) — Lines 1–13 (complete, 13 lines)
5. [`subject/TASK_FIX1.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/subject/TASK_FIX1.md) — Lines 1–19 (complete, 19 lines)
6. [`subject/TASK.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/subject/TASK.md) — Lines 1–27 (complete, 27 lines)
7. [`prior/GEMINI_AUDIT_1_REPORT.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/prior/GEMINI_AUDIT_1_REPORT.md) — Lines 309–389 (81 lines) & Lines 424–446 (23 lines)
8. [`subject/P012_PRODUCTION_ADMISSION_PACKET.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/subject/P012_PRODUCTION_ADMISSION_PACKET.md) — Lines 1–150 (150 lines), continued Lines 151–291 (141 lines; complete, 291 lines)
9. [`sources/03_PRODUCTION_CLOSURE_MATRIX.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/03_PRODUCTION_CLOSURE_MATRIX.md) — Lines 1–65 (65 lines), continued Lines 64–66 (3 lines; complete, 66 lines)
10. [`sources/PATH_D_DECISION_SIGNED_20260912.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/PATH_D_DECISION_SIGNED_20260912.md) — Lines 1–19 (19 lines), continued Lines 19–20 (2 lines; complete, 20 lines)
11. [`sources/REVIEW_POLICY.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/REVIEW_POLICY.md) — Lines 1–77 (complete, 77 lines)
12. [`sources/06_HYPERLIQUID_SETUP.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/06_HYPERLIQUID_SETUP.md) — Lines 1–113 (complete, 113 lines)
13. [`sources/DEPLOY_LINUX_README.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/DEPLOY_LINUX_README.md) — Lines 130–148 (19 lines)
14. [`sources/COMMANDS.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/COMMANDS.md) — Lines 96–105 (10 lines) & Lines 258–266 (9 lines)
15. [`sources/MASTER_WORK_PACKAGE_excerpt.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/MASTER_WORK_PACKAGE_excerpt.md) — Lines 1–38 (complete, 38 lines)
16. [`sources/P012_RATIFICATION_LEAD_NOTE.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/P012_RATIFICATION_LEAD_NOTE.md) — Lines 1–10 (10 lines), continued Lines 10–11 (2 lines; complete, 11 lines)
17. [`sources/P012_ACCEPTANCE_AMENDMENT_20260913.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/P012_ACCEPTANCE_AMENDMENT_20260913.md) — Lines 1–50 (50 lines), Lines 140–220 (81 lines), Lines 330–410 (81 lines) [covering all 19 cited lines]
18. [`sources/PATH_D_DECISION_PACKET.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/sources/PATH_D_DECISION_PACKET.md) — Lines 1–110 (110 lines), Lines 111–210 (100 lines), Lines 211–258 (48 lines; complete, 258 lines) [covering all 18 cited lines]
19. [`subject/SHA256SUMS.txt`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/subject/SHA256SUMS.txt) — Lines 1–3 (complete, 3 lines)
20. [`prior/LEAD_ADJUDICATION_AUDIT_1.md`](file:///C:/LAB/Tradingview_LAB_CLEAN/_gemini_packets_20260913/P012_RISK_PACKET_20260914_B/prior/LEAD_ADJUDICATION_AUDIT_1.md) — Lines 1–8 (complete, 8 lines)

---

## (f) Nonempty NOT VERIFIED

As an independent detection auditor operating strictly read-only and unexecuted, the following items remain unverified:
1. **Unexecuted Runtime & Network State:** No network requests, API calls to Hyperliquid (testnet or mainnet), or execution of bridge code or tests were performed (`SUPPLEMENTAL_UNEXECUTED`).
2. **Hyperliquid 8-Hour Funding Cadence:** Consistent with Section 7 item 5 of the packet, the Hyperliquid 8-hour funding cadence is not verified or established by the cited repository documents (`PATH_D_DECISION_PACKET.md:64, 250` and `P012_ACCEPTANCE_AMENDMENT_20260913.md:367` both state settlement cadence is unestablished).
3. **Five Residual Obligations Enumeration:** The five residual obligations remain verified only as a cited count (`P012_ACCEPTANCE_AMENDMENT_20260913.md:375, 403`), not as a single canonical enumerated source list.
4. **24–27 Internal Content & Order:** Shared requirements 24–27 are retained as a grouped set without individual per-ID ordering or canonical production pointers (`03_PRODUCTION_CLOSURE_MATRIX.md:53`).

---

## (g) Audit Verdict JSON

```json
{
  "part": "P012_RISK_PACKET_GEMINI_B",
  "verdict": "PASS",
  "evidence_class": "SUPPLEMENTAL_UNEXECUTED",
  "delta": {
    "F-01": "RESOLVED",
    "F-02": "RESOLVED",
    "F-03": "RESOLVED",
    "F-04": "RESOLVED",
    "F-05": "RESOLVED",
    "F-06": "RESOLVED",
    "F-07": "RESOLVED",
    "F-08": "RESOLVED",
    "F-09": "RESOLVED"
  },
  "findings": [],
  "required_scope_unread": []
}
```

GEMINI_READ_ONLY_OK